Health Mizuho Upgrades Sarepta Therapeutics to Outperform with New Price Target Mizuho Securities has upgraded shares of Sarepta Therapeutics (NASDAQ: SRPT) from a neutral rating to an outperform rating, as detailed in a research note... Editorial5 hours ago